Arcus Biosciences to present new ARC-20 casdatifan data in kidney cancer at Oct. 20 investor event
Bitget2026/09/22 12:32- Arcus Biosciences set an in-person investor event for Oct. 20, 2026, to disclose new ARC-20 study data for casdatifan in kidney cancer.
- Results have not yet been presented; the update will cover performance across first-line combinations, a second-line combination, and late-line monotherapy.
- Management will frame whether casdatifan can serve as a backbone therapy across treatment lines, a key determinant of commercial positioning.
- Safety readouts are expected to support a first-line registrational trial planned for the fourth quarter of 2026.
- Updated evidence from a second-line regimen will align with a separate registrational study targeted to finish enrollment by end-2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The British Pound rallies on a UK growth upgrade and gives more than half back
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Crypto prices
More
